No abstract available.

No abstract available.
Humans ; Male ; Nursing* ; Urinary Incontinence*

PURPOSE: GH-releasing peptide(GHRP-6) was shown to possess strong GH-releasing activity both in vitro and in vivo. Chemically,GHRP-6 has no primary sequence homology with GHRH. The GH releasing activity of GHRP-6 has been demonstrated in several animal species including humans. GHRPs could have a considerable physiological and clinical useful for treatment of GH deficient and/or non GH deficient short children in the near future. The aim of this study was to evaluate the GH-releasing activity of GHRP-6 in anterior pituitary cell culture and compared to that of GHRH . METHODS: Spraque-Dawley rats were decapitated and pituitary glands were collected in ice-cold PBS. The anterior pituitaries were minced into small fragments and dissociated by enzymatic digestion. These pituitary cells were suspended in Dulbecco' modified Eagle' medium(DMEM) with fetal calf serum at a concentration of 106cells/mL and then plated onto multiwelled dishes at a density of 1.5*05 cells per 6 well plate. GHRP-6 treated group(10-8, 10-7, 10-6 M), GHRH treated group(10-8, 10-7, 10-6 M) and combined GHRP-6 and GHRH treated group were classified. After replacement of each GHRP and/or GHRH+GHRP, the released GH were measured with RIA in 10 min, 20 min, and 30 min. RESULTS: 1) GHRH(10-8) treatment increased GH release by 15.8+/-3.9ng/mL in 0 min., 69.8+/-4.3ng/mL in 10 min. 78.3+/-5.0ng/mL in 20 min. and 67.8+/-7.2ng/mL in 30 min. In case of GHRP-6(10-8M) treatment increased GH release by 11.0+/-1.4 in 0 min., 90.3+/-12.2 in 10 min., 78.3+/-4.5ng/mL in 20 min. and 78.0+/-4.8ng/mL in 30 min. The released GH levels were markedly increased in 10 min. after GHRP-6 and were not singificantly different from that of GHRH. 2)GHRP+GHRH(10-7M+10-8M) treatment increase GH release by 8.8+/-1.5ng/mL in 0 min., 37.8+/-9.3ng/mL in 10 min., 41.3+/-8.1ng/mL in 20 min. and 40.0+/-7.9ng/mL in 30 min. The released GH levels after GHRP+GHRH treatment was not markedly increased statistically compared to GHRH only. CONCLUSION: GHRP-6 could release GH in rat anterior pituitary cell culture and the released GH amounts were not significantly different from that of GHRH. There was no synergistic additive effect in GHRP+GHRH in rat pituitary cell culture.
Animals ; Cell Culture Techniques* ; Child ; Digestion ; Growth Hormone* ; Humans ; Pituitary Gland ; Rats* ; Sequence Homology

Prostate specific antigen (PSA) is known as the most sensitive marker for detecting prostate carcinoma (CaP). Nevertheless, PSA testing lacks sufficient sensitivity and specificity to be considered the perfect tumor marker for the detection of early prostate cancer. PSA exists in the serum in several molecular forms; free PSA and complexed PSA (PSA complexed to alpha-1-antichymotrypsin or a-2-macrogloburin or inter-alpha -trypsin inhibitor). It has been suggested that analysis of level of free to total PSA ratio improves specificily of PSA assays in the early detection of prostate carcinoma. We measured free PSA and total PSA of 367 healthy men aged from 30 to 79 years old using radioimmunoassay (PSA-RIACT and FPSA-RIACT kit) in order to know the normal range of PSA, free PSA and free PSA to total PSA ratio. The mean free to total PSA ratio in normal Korean men is 0.31+/-0.14 and there is no correlation with patient age.
Aged ; Humans ; Male ; Multiple Endocrine Neoplasia Type 1 ; Prostate ; Prostate-Specific Antigen ; Prostatic Neoplasms ; Radioimmunoassay ; Reference Values ; Sensitivity and Specificity

Leiomyosarcoma of the prostate is a rare malignant tumor. It originates from the smooth muscles of the prostatic gland and is usually found during old ages. Prognosis is usually poor especially in childhood. We report a case of leiomyosarcoma of the prostate measured 320gm in 64 years old man.
Humans ; Leiomyosarcoma* ; Middle Aged ; Muscle, Smooth ; Prognosis ; Prostate*

The solid and hematologic cancer are occasionally accompanied by peripheral blood eosinophilia and suggest tumor necrosis or wide dissemination, but the mechanisms underlying this curious relationship remain obscure. The association of this eosinophilic leukemoid reaction with carcinoma seems to occur must frequently with bronchogenic carcinoma. Several mechanisms for this association were considered: eosinophil chemotactic factor, eosinophil mediated by T-lymphocyte, and eosinopoietic hormone. We are here reporting a case of bronchoalveolar cell carcinoma of lung associated with peripheral eosinophilia in a 60-year-old male patient.
Carcinoma, Bronchogenic ; Eosinophilia* ; Eosinophils ; Humans ; Leukemoid Reaction ; Lung* ; Male ; Middle Aged ; Necrosis ; T-Lymphocytes

No abstract available.
Carcinoma, Squamous Cell ; Esophageal Neoplasms ; Neoplasm Metastasis

Cutaneous smooth muscle hamartomas are benign proliferations of smooth muscle bundles within the dermis. They can be congenital or acquired, and most cases are congenital. Congenital smooth muscle hamartomas (CSMHs) usually manifest at birth as well-circumscribed, frequently hypertrichotic, hyperpigmented or skin-colored patches or plaques on trunk or extremities. We report a case of CSMH in a 10 year-old girl, who showed a localized skin-colored patch showing prominent follicular papules on the lateral aspect of her right upper arm, which were found at birth. There was no hypertrichosis and the pseudo-Darier sign was negative. This patchy follicular variant is the less common clinical type of the disease.
Arm ; Dermis ; Extremities ; Female ; Hamartoma* ; Humans ; Hypertrichosis ; Muscle, Smooth* ; Parturition

No abstract available.
Female ; Pregnancy ; Pregnancy, Tubal*

No abstract available.
Carcinoma, Squamous Cell* ; Cervix Uteri* ; Female ; Biomarkers, Tumor*